Compare Heron Therapeutics Inc (HRTX) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nutrien Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Nutrien Ltd trades at $70.31 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 489.8× Heron Therapeutics Inc's market cap, and Nutrien Ltd pays a 3.15% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Nutrien Ltd for 59 Days on average.
| HRTX | NTR | |
|---|---|---|
Market Cap | $68.01M | $33.31B |
Volume | 1,891,941 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $83.94 |
52-Week Low | $0.27 | $53.64 |
Typical Hold Time | 35 Days | 59 Days |
Enterprise Value | $174.75M | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Nutrien (NTR) trades at $69.97, down 1.73% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation at P/E of 14.14. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations, while analyst consensus remains bullish with $76.14 price target.
NTR presents value opportunity with reasonable valuation and strong agricultural market positioning, though faces headwinds from fertilizer price volatility and competitive pressures. The stock's current discount to analyst targets and oversold technical condition suggest potential upside, but investors should monitor input cost trends and global fertilizer demand dynamics closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
